FAIRFIELD, CT, November 28, 2006 – IMS Health (NYSE: RX) today announced that it has successfully integrated anonymized patient-level data (APLD) across its global portfolio of information, analytics and consulting offerings. As a global leader in protecting individual patient privacy, IMS uses de-identified healthcare data to deliver critical, real-world disease and treatment insights. These insights help medical researchers, government agencies, and healthcare and pharmaceutical companies identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.
